NCT02639026 2025-11-25Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersAbramson Cancer Center at Penn MedicinePhase 1 Completed53 enrolled
NCT03238027 2024-05-17A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsSyndax PharmaceuticalsPhase 1 Completed45 enrolled
NCT03162224 2022-08-25Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerMedImmune LLCPhase 1/2 Completed35 enrolled 25 charts
NCT02572687 2021-01-20A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesEli Lilly and CompanyPhase 1 Completed85 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled
NCT02628132 2020-07-07Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsKing Faisal Specialist Hospital & Research CenterPhase 1/2 Completed22 enrolled
NCT02027961 2019-05-17Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneMedImmune LLCPhase 1 Completed68 enrolled